Myriad Genetics Launches Predictive Medicine Testing in Germany, Switzerland and Austria

28-Jun-2001

Myriad Genetics, Inc. (Nasdaq: MYGN), has formed an exclusive collaboration with Bioscientia Ltd., an international reference laboratory company, to provide its family of BRACAnalysis® predictive medicine products in Germany, Switzerland and Austria, the Company announced today.

Bioscientia, based in Ingelheim, Germany is one of the largest reference laboratories in Europe, celebrating its 30th year of service emphasizing high quality, fast and accurate test results. Bioscientia employs over 900 professional and technical specialists serving university, military, and Ministry of Health hospitals, clinics, pharmaceutical companies, and over 6,000 physicians with an extensive collection and logistics network. In 2000, Bioscientia performed over 50,000 tests per workday at its Ingelheim laboratory.

"Bioscientia is a high quality esoteric testing provider and we are pleased to be working with a market leader to broaden access to our BRACAnalysis® tests," said Gregory Critchfield, MD, President of Myriad Genetic Laboratories, Inc. "Individuals at risk of breast cancer and ovarian cancer will have the benefit of Myriad's tests and Bioscientia's superb network and relationship with physicians and hospitals which we believe will assist in the prevention and medical management of these cancers. The expansion of BRACAnalysis® testing in Europe underscores the value of Myriad's predictive medicine discoveries and technologies."

Under the agreement, Bioscientia will send test specimens for the comprehensive BRACAnalysis® full-sequence test to Myriad Genetic Laboratories in Salt Lake City for analysis. All mutations will be tested in Ingelheim as well. Myriad and Bioscientia intend to explore opportunities for additional testing services and other ways to expand their relationship.

"Bioscientia is pleased to be working with the world leader in predictive medicine. Leveraging our international access to provide Myriad's cancer predictive medicine tests is an important step in our goal of helping many patients and their doctors receive high quality, rapid results in order to better manage, diagnose and prevent these diseases," said Jochen Decker, M.D., Chief Executive Officer and Medical Director for Bioscientia. "As a market leader, we are constantly looking for new, world class diagnostic technologies that help fight disease. Myriad has the technology and the products that form the type of company that is a good fit with Bioscientia."

https://www.chemeurope.com/en/news/3678/myriad-genetics-launches-predictive-medicine-testing-in-germany-switzerland-and-austria.html